Low-Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy
the ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Robinson, Thompson G.
Wang, Xia
Arima, Hisatomi
Bath, Philip M.
Billot, Laurent
Broderick, Joseph P.
Demchuk, Andrew M.
Donnan, Geoffery A.
Kim, Jong S.
Lavados, Pablo M.
Lee, Tsong Hai
Lindley, Richard I.
Martins, Sheila C.O.
Olavarria, Veronica V.
Pandi

© 2017 American Heart Association, Inc. Background and Purpose'Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Methods'Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior APT use.
Primary outcome at 90 days was the combined end point of death or disability (modified Rankin Scale [mRS] scores, 2-6). Other outcomes included mRS scores 3 to 6, ordinal mRS shift, and symptomatic intracerebral hemorrhage by various standard criteria. Re